GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » OpGen Inc (NAS:OPGN) » Definitions » Revenue per Share

OpGen (OPGN) Revenue per Share : $0.66 (TTM As of Sep. 2023)


View and export this data going back to 2015. Start your Free Trial

What is OpGen Revenue per Share?

OpGen's revenue per share for the three months ended in Sep. 2023 was $0.08. OpGen's revenue per share for the trailing twelve months (TTM) ended in Sep. 2023 was $0.66.

Warning Sign:

OpGen Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue Per Share Growth Rate of OpGen was -56.10% per year. During the past 3 years, the average Revenue Per Share Growth Rate was -70.90% per year. During the past 5 years, the average Revenue Per Share Growth Rate was -75.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for OpGen's Revenue per Share or its related term are showing as below:

OPGN' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -81.2   Med: -70.9   Max: -5.8
Current: -70.9

During the past 10 years, OpGen's highest 3-Year average Revenue Per Share Growth Rate was -5.80% per year. The lowest was -81.20% per year. And the median was -70.90% per year.

OPGN's 3-Year Revenue Growth Rate is ranked worse than
98.79% of 742 companies
in the Medical Devices & Instruments industry
Industry Median: 7.5 vs OPGN: -70.90

OpGen Revenue per Share Historical Data

The historical data trend for OpGen's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OpGen Revenue per Share Chart

OpGen Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 196.40 43.20 5.33 2.35 1.07

OpGen Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.19 0.27 0.20 0.12 0.08

Competitive Comparison of OpGen's Revenue per Share

For the Medical Devices subindustry, OpGen's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OpGen's PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, OpGen's PS Ratio distribution charts can be found below:

* The bar in red indicates where OpGen's PS Ratio falls into.



OpGen Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

OpGen's Revenue Per Share for the fiscal year that ended in Dec. 2022 is calculated as

Revenue Per Share (A: Dec. 2022 )=Revenue (A: Dec. 2022 )/Shares Outstanding (Diluted Average) (A: Dec. 2022 )
=2.607/2.442
=1.07

OpGen's Revenue Per Share for the quarter that ended in Sep. 2023 is calculated as

Revenue Per Share (Q: Sep. 2023 )=Revenue (Q: Sep. 2023 )/Shares Outstanding (Diluted Average) (Q: Sep. 2023 )
=0.699/8.778
=0.08

Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.66

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OpGen  (NAS:OPGN) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


OpGen Revenue per Share Related Terms

Thank you for viewing the detailed overview of OpGen's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


OpGen (OPGN) Business Description

Traded in Other Exchanges
Address
9717 Key West Avenue, Suite 100, Rockville, MD, USA, 20850
OpGen Inc is a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease. It is developing molecular information products and services for healthcare settings, helping to guide clinicians with rapid and actionable information about life-threatening infections, improve patient outcomes, and decrease the spread of infections caused by MDROs. Its proprietary DNA tests and informatics address the rising threat of antibiotic resistance by helping physicians and other healthcare providers optimize care decisions for patients with acute infections. The company's product candidates and services combine its Acuitas molecular diagnostics and Acuitas Lighthouse informatics platform for use with its curated MDRO knowledge base.
Executives
Yvonne Schlaeppi director 600 EAST GREENWICH AVENUE, WEST WARWICK X1 02893
Johannes Bacher officer: Chief Operating Officer 9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850
Albert Weber officer: Chief Finanical Officer MARIENBURGER STR. 7, BERLIN 2M 10405
Oliver Schacht director, officer: Chief Executive Officer 9717 KEY WEST AVENUE, SUITE 101, ROCKVILLE MD 20850
Evan/ Fa Jones director, officer: Chief Executive Officer C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
William E. Rhodes director C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850
Curetis N.v. In Liquidation 10 percent owner MAX-EYTH-STRASSE 42, HOLZGERLINGEN 2M 71088
Mario Crovetto director C/O OPGEN, INC., 9717 KEY WEST AVE., SUITE 100, ROCKVILLE MD 20850
Prabhavathi Fernandes director 114 MILTON AVENUE, CHAPEL HILL NC 27514
Vadim M. Sapiro officer: Chief Information Officer C/O OPGEN, INC,, 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
Timothy C Dec officer: Chief Financial Officer C/O OPGEN, INC., 708 QUINCE ORCHARD ROAD, SUITE 205, GAITHERSBURG MD 20878
R Don Elsey director 2273 RESEARCH BLVD, SUITE 400, ROCKVILLE MD 20850
Jven Capital, Llc 10 percent owner P.O. BOX 60207, POTOMAC MD 20859
Tina Susan Nova director C/O ARENA PHARMACEUTICALS, INC., 6166 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Harry J D'andrea director 6480 DOBBIN ROAD, COLUMBIA MD 21045